

Clinical pharmacology: Now, More than Ever!

Eastern
European Time
(EET)

Saturday June 25 2022

13:00	Pre-meeting for Young Clinical Pharmacologists
13:00-13:10	Introduction by Carla Sans and Émilie Jouanjus
13:10-13:30	Updates on the collaborative research project on medical cannabis conducted by Young Clinical Pharmacologists by Émilie Jouanjus
13:30-13:50	"Research and mobility support for Young Clinical Pharmacologists" - current resources and future wish list by Carla Sans
13:50 - 14:00	Break
14:00 - 14:40	"Speed pharmacology dating" among Young Clinical Pharmacologists
14:40 - 14:50	Coffe break and networking
14:50 - 15:50	www.prescribingeducation.eu (Presentation of the platform, Q&A, and discussion about needs and ideas of future contributions) by Erik Donker and Chiel Bakkum
15:50 - 16:00	Conclusion by Carla Sans and Émilie Jouanjus

Sunday June 26 2022

SKALKOTAS HALL

09:00	<p>Welcome and introduction: "Clinical pharmacology; Now, more than ever!" by Vangelis Manolopoulos, president of the local organizing committee and Pierre Marquet, EACPT president</p>		
09:20	<p>Plenary lecture #1: "Hepatic adverse drug reactions to antimicrobials: predictable?" by Ann K. Daly Chairs: Vangelis Manolopoulos, Jamie Coleman, Pierre Marquet</p>		
10:00	<p>Refreshment break</p>		
	<p>SKALKOTAS HALL</p>		
10:40	<p>Plenary lecture #2: "Regulation at Speed" by Marco Cavaleri</p>		
11:20	<p>Lifetime achievement award and lecture by Kim Brosen Chairs: Vangelis Manolopoulos, Jamie Coleman, Pierre Marquet</p>		
12:00	<p>Lunch break</p>		
13:00	<p>Poster Presentations</p>		
	<p>MC3</p>	<p>SKALKOTAS HALL</p>	<p>MC2</p>
14:00	<p>S1a: Pharmacogenomics in clinical practice (co-organized with ESPT, European Society of Pharmacogenomics and Personalized Therapy) Chairs: Vangelis Monolopoulos, Julia Stingl</p>	<p>S1b: Immunopharmacology Chairs: Annalisa Capuano, Ioanna Andreadou</p>	<p>S1c: COVID-19 Update on therapies Chairs: Miia Turpeinen, Josep Maria Miro</p>
	<p>Speaker 1: Adrian Llerena Pharmacogenetics clinical Implementation in European Health Services: Examples from Spain</p> <p>Speaker 2: Mikko Niemi Pharmacogenomics of cholesterol-lowering therapy – implementation into clinical practice and future perspectives</p>	<p>Speaker 1: Xiaoli Meng (V) Role of immunology/hypersensitivity in drug toxicity</p> <p>Speaker 2: Liberata Sportiello (V) Immune checkpoint inhibitors (ICIs) and immune-related adverse drug reactions: focus on their neurotoxicity</p>	<p>Speaker 1: Roger Paredes (V) Treatment</p> <p>Speaker 2: César Sanz Prophylaxis (mRNA vaccines)</p>
14:54-15:07	<p>196 - Qinglian Zhai (V) Added value of DPYD whole exon sequencing to explain severe fluoropyrimidine-induced toxicity</p>	<p>14:54-15:07 233 - Kenza Abouir Impact of obesity on dexamethasone pharmacokinetic in COVID-19 hospitalized patients: an observational exploratory study</p>	<p>14:54-15:07 70 - Roos Sablerolles Immunogenicity 5-months after homologous or heterologous booster vaccination in Health Care Workers primed with Ad26.COV2.S</p>
15:07-15:20	<p>11 - Camille Lenoir (V) Impact of the genotype and phenotype of CYP3A and P-GP on the apixaban and rivaroxaban blood concentrations in real-world setting</p>	<p>15:07-15:20 238 - Clarisse Brossier Intestinal permeability in transplant patients: are systemic short-chain fatty acids an early biomarker?</p>	<p>15:07-15:20 76 - Vânia Rocha Geographic variation in top-10 prescribed medication and potentially inappropriate prescription in Portugal: an ecological study of 2.2 million older adults</p>
15:20-15:33	<p>208 - Georgia Ragia Direct oral anticoagulant-related bleeding in atrial fibrillation patients alters DNA methylation of NOS3 and KDR genes</p>		<p>15:20-15:33 66 - Simon Dedroogh SARS-CoV-2-Antibodies after different VaccineCombinations in hospital staff (HelCo-Vac Study)</p>
15:30	<p>Refreshment break</p>		
15:40	<p>S2a: OMICS and Targeted Biomarkers Chairs: Ann Daly, Arantxa Sancho Lopez</p>	<p>S2b: Joint meeting with IUPHAR Chairs: Ingolf Cascorbi, Pierre Marquet</p>	<p>S2c: Mixed Oral Presentations (1) Chairs: Michiel Van Agtmael, Pau Acubilla</p>
	<p>Speaker 1: Prof Maribel Lucena Drug induced liver diseases</p> <p>Speaker 2: Gerd-Achim Kullak-Ublick (V) New biomarkers</p>	<p>Speaker 1: Ingolf Cascorbi IUPHAR – Chances of international cooperations of pharmacological societies</p> <p>Speaker 2: Michael Spedding Challenges of drug development in Covid-19</p>	<p>15:40-15:53 97 - Haithem Chtioui Safety, tolerability and pharmacokinetic profile of Macozinone (PBTZ169) formulated as native crystal powder: multiple ascending-doses, phase-Ib trial in healthy volunteers</p> <p>15:53-16:06 260 - Irina Vilyum The use of screening data for the carrier of multi-resistant microorganisms to determine strategies for antibiotic prophylaxis and treatment</p>
16:34-16:47	<p>54 - Areti-Maria Vasilogianni Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients with Colorectal Cancer Liver Metastasis</p>	<p>Speaker 3: Caroline Samer The Clinical and Translational Section – Link to WHO</p>	<p>16:06-16:19 219 - Laura Aurinsalo Safety and applicability of a phenotyping cocktail of seven cytochrome P450 -selective substrate drugs for clinical trials</p>
16:47-17:00	<p>231 - Fani Koutsougianni Pharmacological characterization of a novel lipid-rich breast cancer patient-derived xenograft</p>		<p>16:19-16:32 133 - Jenny Dimakos (V) Peptidomimetic structure of dipeptidyl peptidase-4 inhibitors and the risk of sulfonylurea-induced severe hypoglycemia: a population-based cohort study</p> <p>16:32-16:45 96 - Sophie Fedrizzi Multiple sclerosis drugs and dental and gingival disorders: an observational retrospective study and disproportionality analysis in the world pharmacovigilance database</p>
17:10	<p>Shimadzu Symposium: "Innovative LC-MS/MS approaches for TDM" Prof. Franck Saint-Marcoux</p>	<p>IUPHAR Executives' Meeting</p>	<p>Round-table: European training in drug-drug interaction assessment: a comprehensive approach</p>
18:30	<p>WELCOME CEREMONY & RECEPTION Congress Foyer</p>		
20:00			

Monday June 27 2022

07:00	EACPT Run		
08:00	<p style="text-align: center;">Workshop 1:</p> <p style="text-align: center;">Debate session: Human challenge trials</p> <p style="text-align: center;">Chairs: David Webb, Joaquin Saez</p> <p style="text-align: center;">Speakers: Garth Rapeport and Susan Bull</p>		<p style="text-align: center; color: red;">CANCELLED</p> <p style="text-align: center;">(Workshop 2: Happy Patient Project)</p> <p style="text-align: center;">Chair: Jamie Coleman</p>
	MC3	SKALKOTAS HALL	MC2
09:00	<p style="text-align: center;">S3a: Advanced Therapies</p> <p style="text-align: center;">Chairs: Arantxa Sancho Lopez, Georgios Papazisis</p> <p>Speaker 1: Concepción Payares ORTHOUNION. An European, multinational experience</p> <p>Speaker 2: Eulalia Olesti (V) Hospital exemption: The happy end of the journey</p>	<p style="text-align: center;">S3b: Clinical Pharmacology of cardiovascular drugs (joint meeting with EPBAR)</p> <p style="text-align: center;">Chairs: Ioanna Andreadou, Andreas Papapetropoulos</p> <p>Speaker 1: John Parisis (V) SGLT-2 inhibitors in heart failure</p> <p>Speaker 2 : Gemma Vilahur Antithrombotic therapy in diabetes</p>	<p style="text-align: center;">S3c: New ways of learning Clinical pharmacology</p> <p style="text-align: center;">Chairs: Michiel Van Agtmael, Jamie Coleman</p> <p>9:00-9:15 Rowan Sultan Interprofessional learning</p> <p>9:15-9:30 Jamie Coleman Discussion on the table and with the audience</p> <p>9:30-9:50 Rashudy Mahomedradja & Jamie Coleman Debate: Learning medication reviews is useful</p> <p>9:50-10:00 All Discussion on the table and with the audience and speakers</p> <p>10:00-10:10 57 - Michael Reumerman An inter-professional student-run medication review programme. Reducing adverse drug reactions in a memory outpatient clinic: A controlled clinical trial</p> <p>10:10-10:20 56 - Michael Reumerman An inter-professional student-run medication review programme: The clinical outcomes of a clinical controlled trial in a geriatric outpatient clinic</p> <p>10:20-10:30 127 - Michiel Bakkum Novel teaching resources for the European Open Platform for Prescribing Education (EurOP2E) – a nominal group technique study</p>
10:30	Refreshment break		
11:00	<p style="text-align: center;">S4b: Mixed Oral Presentations (2)</p> <p style="text-align: center;">Chairs: Carla Sans, Emilie Jouanjus</p>	<p style="text-align: center;">S4a. Session organized by BPS: Clinical Prize Lectures</p> <p style="text-align: center;">Chairs: Reecha Sofiat, Vangelis Manolopoulos</p>	<p style="text-align: center;">S4c: CPT training across Europe</p> <p style="text-align: center;">Chairs: Jelle Tichelaar, Emilio Sanz</p>
11:00-11:13	<p>254 - Chrissy Pourzitaki Impact of OPRM1 and ABCB1 gene polymorphisms on the perioperative remifentanyl requirements and pain perception in patients undergoing elective thyroidectomy</p>	<p>Speaker 1: Richard Turner Pharmacogenomics v2.0 (BPS Dunlop Prize Lectureship 2021)</p>	<p>11:00-11:15 Erik Donker Europ2E a digital platform</p>
11:13-11:26	<p>132 - Jenny Dimakos Concomitant use of sulfonylureas and warfarin and the risk of severe hypoglycemia: a population-based cohort study</p>	<p>Speaker 2: Joel Tarning (V) Pharmacological considerations in antimalarial treatments (Grahame-Smith Prize 2020)</p>	<p>11:15-11:30 Emilio Sanz Discussion on the table and with the audience</p>
11:26-11:39	<p>53 - Luz M Gonzalez Genetic variability in phospholipase genes affect nephrosclerosis risk and associated cardiovascular outcomes</p>	<p>Short talk 1: Lauren Walker Inclusivity and representation in clinical trial design</p>	<p>11:30-12:30 Chiel Bakkum Workshop Escaperoom</p>
11:39-11:52	<p>8 - Benjamin Skov Kaas-Hansen Eliciting drug safety signals from patient records: a language-agnostic approach</p>	<p>Short talk 2: Marie Fisk (V) Sustainable medicines for planetary health</p>	
11:52-12:05	<p>257 - Natalia Atzemian Unraveling potential pharmacological target genes from transcriptomic profiles in the development of persistent atrial fibrillation: A bioinformatics approach</p>		
12:05-12:18	<p>270 - Constantin Tamvakopoulos Therapeutic drug monitoring of anticancer monoclonal antibodies by mass spectrometry approaches</p>		
12:30	Lunch / Poster Viewing		
13:00			
13:30			

Monday June 27 2022

SKALKOTAS HALL

14:00	<p align="center">Plenary Lecture #3: "Lessons learned from the COVID-19 pandemics" by Meletios A. Dimopoulos Chair: Pierre Marquet, Gerard Rongen, Vangelis Manolopoulos</p>		
14:35	<p align="center">Plenary Lecture #4: "New Artificial intelligence tools to the service of medical questions" by Mihaela van der Schaar Chair: Pierre Marquet, Gerard Rongen, Vangelis Manolopoulos</p>		
15:10	<p align="center">Refreshment break</p>		
	MC3	SKALKOTAS HALL	MC2
15:30	<p align="center">S5a: Advanced Drug Delivery / Formulations Chairs: Janne Backman, Caridad Pontes</p>	<p align="center">S5b: Systems Pharmacology and Artificial Intelligence in Clinical Pharmacology and Therapeutics (Joint session with ACCP) Chairs: Artemis Chatzigeorgiou, Julia Stingl</p>	<p align="center">S5c: Changing the Benefit-Risk Balance of Medicines (challenging the mantra) Chairs: Arantxa Sancho Lopez, Pierre Marquet</p>
16:50	<p>Speaker 1: Giovanna Lollo (V) Advanced nanomedicine for cancer immunotherapies : Challenges and opportunities</p> <p>Speaker 2: Giuseppe Curigliano (V) Antibody-drug conjugates in solid tumors: will they hold the promise?</p> <p>Speaker 3: Robert Langer (V) From nanotechnology to mRNA therapies and whats to come</p>	<p>Speaker 1: Christian Lovis (V) AI / machine Learning</p> <p>Speaker 2: Claudia Sala Synthetic data generation, machine learning and Bayesian models for outcome prediction in drug development and personalized medicine</p> <p>Speaker 3: Don Mager Toward Application of Systems Analysis to Guide Decisions in Clinical Pharmacology and Therapeutics</p>	<p>Speaker 1: Ed Waddingham (V) New ways of appraising benefit-risk balance</p> <p>Speaker 2: Bahri Priya (EMA) (V) New ways of appraising the benefit-risk balance</p> <p>16:11-16:24 36 - Cathy Gaillard French academic and industrial experience on financial compensation of participants in clinical trials</p> <p>16:24-16:37 130 - Pau Alcubilla Antineoplastic drug approvals by European Medicines Agency (EMA) and Food and Drug Administration (FDA) between 2018-2021. Evaluation of potential differences</p> <p>16:37-16:50 202 - Lucía Arellano What has happened to medicines after a Conditional Marketing Authorisation (CMA) was granted by European Medicines Agency (EMA) from 2006-2020</p>
17:00	<p align="center">Poster Viewing</p>		<p align="center">EACPT Council Meeting</p>
18:30			
19:30	<p align="center">Congress Dinner Restaurant Garbi (departure by bus 19:30)</p>		
23:30			

Tuesday June 28 2022

	MC3	SKALKOTAS HALL	MC2
08:00	Workshop 3: Pharmacovigilance in Practice (Greek Society of Pharmacology) Chair: Georgios Papazisis Speaker: Georgios Papazisis	Workshop 4: What makes a good journal peer review Chair: Julia Stingl Speakers: Emilio Sanz and Ann Daly Interactive Workshop with true article examples and reviews	Workshop 5: Early access to innovative medicines Chairs: Arantxa Sancho Lopez, Caridad Pontes Speakers: Caridad Pontes and Montse Gasol
09:00	EACPT Executive Committee Meeting	Refreshment break	
10:00	S6a: Joint session with IATDMCT: TDM of mAbs Chairs: Dario Cataneo, Pierre Marquet Speaker 1: Dirck Jan Moes Model informed precision dosing of biologics: Challenges and opportunities Speaker 2: Joseph Ciccolini (V) TDM of mAbs: is PK actionable?	S6b: Public-private collaboration in drug repurposing: challenges and opportunities Chairs: Gerard Rongen, George Kolios Speaker 1: Jan-Hein Cornel (V) Public-private collaboration in drug repurposing: challenges and opportunities Speaker 2: Lakshminarayan Ranganathah & Nick Sireau (V) Collaboration of patients and scientists: Ongoing success story of OD for alkaptonuria	S6c: Special populations in drug-development and rational prescribing Chairs: Florian Naudet, Annalisa Capuana Speaker 1: Jean-Christophe Lega Use of race/ethnicity as population descriptors in pharmacology: benefits and challenges Speaker 2: Mario Braakman (V) Cultural determinants of drug response
10:51-11:04	226 - Lieke Mitrov-Winkelmoelen A retrospective study of anti-xa activity in patients with renal insufficiency receiving renal-based reduced or not-reduced therapeutic doses of dalteparin	210 - Imke Bartelink Pharmacokinetics and Pharmacodynamics for Optimal Drug Repurposing of Imatinib from Cancer to COVID-19	24 - Marie-Laure Laroche Applications of the REMEDI[e]S tool: implicit and explicit criteria for optimizing drug prescribing in older adults
11:04-11:17	194 - Niklas Kehl Development and validation of an LC-MS method for drug exposure measurement of 57 oral antitumor drugs in human plasma	14 - Mads Kjolby Repurposing the Japanese heartburn drug camostat to potential antiviral treatment in COVID-19 – a human trial.	155bis - Valentin Skryabin Effects of cyp3a4 genetic polymorphisms on the efficacy and safety profiles of diazepam in patients with alcohol withdrawal syndrome
11:17-11:30	99 - Rim Charfi Is there an association between valproic acid serum levels and remission in epileptic children?	23 - Patricia Rodríguez-Fortúnez (V) Defibrotide in the prevention and treatment of acute respiratory distress syndrome in patients with COVID-19. Preliminary safety results update.	38 - Matthieu Roustit (V) Placebo response in Raynaud's Phenomenon clinical trials: the prominent role of regression towards the mean
11:30	EACPT General Assembly		
12:30	Lunch / Poster Viewing		
	Meet the WCP2023 President for a drink - British Pharmacological Society Stand		
	Poster Presentations		
13:30	S7a: Mixed Oral Presentations (3) Chairs: Joaquin Saez, Vangelis Manolopoulos	S7b: Psychopharmacology Chairs: Georgios Papazisis, Mimi Stokke Opdal	S7c: Physiology-based pharmacokinetic modeling to guide personalized drug dosing Chairs: Gerard Rongen, Janne Backman
13:30-13:43	30 - Ji Yun Park Pharmacokinetics and pharmacodynamics of intravenous and oral fexuprazan, a potassium-competitive acid blocker, after single administration in healthy Korean and Chinese	Speaker 1: Emilie Jouanjus Pharmacological facts about cannabidiol	Speaker 1: Amin Rostami-Hodjegan On the verge of impossibility: caring for all permutations of comorbidities influencing fate of drugs
13:43-13:56	37 - Anna Teegelbekkers Effect of tacrolimus formulation (prolonged-release vs. immediate-release) on the extent of the pharmacokinetic interaction with St. John's wort	Speaker 2: Ingvild Odsbu (V) Trends in use of prescribed opioids in Norway – should we be concerned?	Speaker 2: Rick Greupink (V) Drug dosing during pregnancy and in children, how can PBPK modeling help?
13:56-14:07	108 - Antonio F Caballero-Bermejo Clinical characterization and prognosis outcomes of carbon monoxide poisoning in Spain. The AMICO study	129 - Debbie Zittema Use of maximal urine concentrating capacity markers to evaluate lithium-induced nephrogenic diabetes insipidus	63 - Hyun Chul Kim Pharmacokinetics and pharmacodynamics of HIP1601, a novel dual delayed-release esomeprazole, compared to a conventional delayed-release esomeprazole in healthy male subjects
14:07-14:20	64 - Rostam Osanlou The identification of adverse drug reactions in medical hospital admissions: A one month prospective analysis	126 - Archana Mishra A randomized controlled trial to evaluate the effect of alpha lipoic acid in patients with treatment resistant schizophrenia	110 - Pedro Guerra López Evolution of 25(OH)D plasma levels in adults with hypovitaminosis D after a 4-month treatment with calcifediol: An interim analysis
14:20-14:33	80 - Anssi Mykkänen Comprehensive pharmacogenomics study of simvastatin pharmacokinetics: major role of SLCO1B1 and CYP3A4		
14:33-14:46	22 - Charles Khouri (V) Risk of skin ulcer and use of cox-2 inhibitors: a national population-based nested case control study		
15:00	Presentation of Awards and Closing Ceremony		
16:00			